Breast Cancer

The separation between those who travel for care compared to those who go to the local hospital may drive inequalities in health care.

The therapy sustained IDFS benefit compared with ET alone.

Heather McArthur, MD, clinical director of breast oncology at UT Southwestern Medical Center, discusses the toxicities associated with antibody-drug conjugates (ADCs) used in breast cancer treatment at the 2023 San Antonio Breast Cancer Symposium.

Troy Bremer, PhD, chief scientific officer at PreludeDx, discusses biosignature model and it's potential in predicting radiation therapy response for those with early-stage invasive breast cancer.

Almost 80% of patients have now stopped treatment with ribociclib, but benefit persists and is greater than it was 6 months ago, according to the presenter.

Study results indicate insignificant differences between PFS and OS in patients with HR[+]/HER2[-] breast cancer who received either palbociclib-letrozole or palbociclib-fulvestrant treatment.

In an interview at the 2023 San Antonio Breast Cancer Symposium, Ana Ferrigno Guajardo, MD, discussed research into the safety and efficacy of taxane-based chemotherapy use in pregnant patients with breast cancer.

As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.

Gabriel N. Hortobagyi, MD, MACP, FASCO, a professor at the University of Texas MD Anderson Cancer Center, discussed the final data on invasive disease-free survival from the NATALEE trial of ribociclib in combination with a nonsteroid aromatase inhibitor (NSAI).

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

Patients with breast cancer who underwent chemotherapy and skipped RNI did not face an increased risk of disease recurrence or death 5 years post-surgery.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

In the first-line setting, inavolisib plus palbociclib and fulvestrant improved PFS in patients with HR-positive breast cancers; however, further research is needed to understand the trends in OS.

Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

In addition to predicting breast cancer outcomes, the AI tool can help determine effective treatment options in patients, sparing them from unnecessary treatments.

The investigators note that continued support during breast cancer treatment is necessary for patient comfort beyond diagnosis and the initial phases of treatment.

TcdBFBD, derived from a toxin found in Clostridium difficile, was tested in mouse models that mimicked different subtypes of breast cancer.

The study findings indicate that health care professionals significantly underreport symptoms compared to patients with breast cancer, with reported comorbidities varying.

Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.

Researchers determined that simultaneously targeting the BRD4 and LOXL2 proteins disrupts their interaction and inhibits the growth of triple-negative breast cancer cells.

Compared to endocrine therapy alone, the combination of ribociclib and endocrine therapy lowered the risk of cancer recurrence in patients with early breast cancer by 25.2%.